Detralex, 1000 mg/10 ml suspension 10 ml 30 pcs

Detralex® has venotonic and angioprotective properties. The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to indexes of venous hemodynamics.

A statistically significant dose-dependent effect of the drug Detralex® has been demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, and time of venous emptying. An optimal dose-effect ratio was observed with administration of 1000 mg/day.

Detralex® increases venous tone: venous occlusion plethysmography has shown a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders after therapy with Detralex® a statistically significant (in comparison with placebo) increase of capillary resistance evaluated by angiostereometry was noted.

Therapeutic effectiveness of Detralex® has been proven in the treatment of chronic diseases of lower limb veins and in the treatment of hemorrhoids.

Detralex® reduces undesirable side effects of invasive methods of treatment of chronic venous diseases (it reduces frequency of undesirable side effects of surgical and endovascular treatment of varicose veins: intensity of postoperative pain syndrome, edema and severity of bleeding after endovascular and surgical treatment reduces significantly).

Pharmacokinetics

The main excretion of the drug is with the feces. With urine, on average, about 14% of the administered amount of the drug is excreted. T1/2 is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Indications

Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Treatment of symptoms of venous-lymphatic insufficiency:

– pain;

– spasms of the lower extremities;

– feeling of heaviness and fullness in the legs;

– “tired” legs.

Treatment of manifestations of venous-lymphatic insufficiency:

– swelling of the lower extremities;

– trophic changes in the skin and subcutaneous tissue;

– venous trophic ulcers.

Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

Detralex® has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics.

A statistically significant dose-dependent effect of the drug Detralex® was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 1000 mg/day.

Detralex® increases venous tone: using venous occlusion plethysmography, a decrease in the time of venous emptying was shown. In patients with signs of severe microcirculation disorders after treatment with Detralex®, there is a (statistically significant, compared to placebo) increase in capillary resistance, assessed by angiostereometry.

The therapeutic effectiveness of the drug Detralex® has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Detralex® reduces undesirable side effects of invasive methods of treating chronic venous diseases (reduces the frequency of undesirable side effects during surgical and endovascular treatment of varicose veins: significantly reduces the intensity of postoperative pain, swelling and severity of hemorrhages after endovascular and surgical treatment).

Pharmacokinetics

The main excretion of the drug occurs in feces. On average, about 14% of the dose taken is excreted in the urine. T1/2 is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Special instructions

Before starting to use the drug Detralex®, the patient is recommended to consult a doctor.

In case of exacerbation of hemorrhoids, the prescription of Detralex® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the “Dosage regimen” section. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy.

In the presence of venous circulation disorders, the maximum effect of treatment is ensured by a combination of therapy with a healthy (balanced) lifestyle; It is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings (compression stockings) helps improve blood circulation.

The patient should immediately consult a doctor if the condition worsens or does not improve during treatment.

Impact on the ability to drive vehicles and operate machinery

The drug does not affect the ability to drive a car or perform work that requires a high speed of mental and physical reactions.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

1 sachet (10 ml)

purified micronized flavonoid fraction 1000 mg, incl. diosmin 900 mg (90%), flavonoids in terms of hesperidin 100 mg (10%)

Excipients:

citric acid – 12.5 mg,

orange flavor – 15 mg,

maltitol – 1800 mg,

sodium benzoate – 15 mg,

xanthan gum – 50 mg,

purified water q.s. – up to 10 ml.

Contraindications

– hypersensitivity to the active substance or excipients included in the drug;

– fructose intolerance.

The drug is not recommended for nursing women.

Side Effects

Side effects of Detralex® observed during clinical trials were mild. Mostly gastrointestinal disorders were observed (diarrhea, dyspepsia, nausea, vomiting).

While taking the drug Detralex®, the following side effects were reported in the following gradation: very often (>1/10), often (>1/100.1/1000.1/10,000,

From the side of the central nervous system: rarely – dizziness, headache, general malaise.

From the gastrointestinal tract: often – diarrhea, dyspepsia, nausea, vomiting; infrequently – colitis; unspecified frequency – abdominal pain.

From the skin: rarely – skin rash, itching, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema.

The patient should inform the doctor about the appearance of any, incl. unwanted reactions and sensations not mentioned in the instructions, as well as changes in laboratory parameters during therapy.

Interaction

There were no drug interactions with Detralex®.

The patient should inform the attending physician about all medications taken.

Overdose

No cases of overdose have been described.

In case of overdose of the drug, the patient should immediately seek medical help.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 30°C.

Shelf life

3 years.

Manufacturer

Uniter Liquid Manufacturing, France